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ABSTRACT
Background. Mantle cell lymphoma (MCL) has the worst prog-
nosis of B-cell subtypes owing to its aggressive clinical disease
course and incurability with standard chemo-immunotherapy.
Options for relapsed MCL are limited, although several single
agents have been studied. Lenalidomide is available in Italy for
patients with MCL based on a local disposition of the Italian
Drug Agency.
Subjects, Materials, and Methods. An observational retrospec-
tive study was conducted in 24 Italian hematology centers with
the aim to improve information on effectiveness and safety of
lenalidomide use in real practice.
Results. Seventy patients received lenalidomide for 21/28 days
with a median of eight cycles. At the end of therapy, there were
22 complete responses (31.4%), 11 partial responses, 6 stable
diseases, and 31 progressions, with an overall response rate of
47.1%. Eighteen patients (22.9%) received lenalidomide in com-
bination with either dexamethasone (n5 13) or rituximab
(n5 5). Median overall survival (OS) was reached at 33 months
and median disease-free survival (DFS) at 20 months: 14/22
patients are in continuous complete response with a median of
26 months. Patients who received lenalidomide alone were
compared with patients who received lenalidomide in combina-
tion: OS and DFS did not differ. Progression-free survivals are
significantly different: at 56 months, 36% in the combination
group versus 13% in patients who received lenalidomide alone.
Toxicities were manageable, even if 17 of them led to an early
drug discontinuation.
Conclusion. Lenalidomide therapy for relapsed MCL patients is
effective and tolerable even in a real-life context. The Oncologist
2018;23:1–6
Implication for Practice: Several factors influence treatment choice in relapsed/refractory mantle cell lymphoma (rrMCL), and the
therapeutic scenario is continuously evolving. In fact, rrMCL became the first lymphoma for which four novel agents have been
approved: temsirolimus, lenalidomide, ibrutinib, and bortezomib. The rrMCL therapeutic algorithm is not so well established
because data in the everyday clinical practice are still poor. Lenalidomide for rrMCL patients is effective and tolerable even in a real-
life context.
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INTRODUCTION
Mantle cell lymphoma (MCL) is an uncommon type of non-
Hodgkin lymphoma (NHL) comprising <10% of all newly diag-
nosed patients. Nevertheless, there has been a significant
increase in the MCL incidence over the past 2 decades, mostly
among older patients [1]. Classified as an aggressive NHL sub-
type, MCL has the worst prognosis among the B-cell subtypes
due to its aggressive clinical disease course and its inability to
be treated with standard chemotherapy.
Although MCL is a rare subtype of NHL, proactive research
efforts fueled by challenges in the management of this disease
have led to an increase in median overall survival (OS) of 2.5
years in the last 20 years. This OS improvement is mostly due
to the use of dose-intensive strategies, particularly cytarabine-
containing regimens (with or without high-dose therapy [HDT]
followed by autologous stem cell transplantation [ASCT] consol-
idation), which are associated with deeper remission (and
higher molecular complete response [CR] rate), as well as due
to better salvage therapies [2, 3]. MCL became the first lym-
phoma for which four novel agents have been approved in the
relapsed/refractory setting: temsirolimus (only in Europe), lena-
lidomide, ibrutinib, and bortezomib (the last agent is approved
only in the U.S., both in relapsed/refractory [rr] disease and
in first-line combination therapy) [4–9]. Study findings con-
firm continuous improvement in the outcomes of MCL
patients over the past decades, but they also highlight the
challenge of improving long-term outcomes, particularly
among older patients [1].
In routine practice (i.e., outside a clinical trial setting), the
outcome of rrMCL remains overall unchanged both with stand-
ard immunochemotherapy and even after HDT-ASCT. In fact,
most patients still relapse and frequently develop chemore-
sistance. The persistent lack of consensus for the treatment
of rrMCL and the different geographical approval of the
abovementioned single agents explain the rather impressive
variability in the management of these patients across coun-
tries [9, 10].
Lenalidomide, an immunomodulator drug with direct anti-
neoplastic effects, was recently approved in the U.S. for rrMCL.
Several phase II studies on lenalidomide have provided sub-
stantial overall response rate (ORR; 28%–53%) with durable
activity in heavily pretreated patients [3, 5, 6, 9, 11]. In the
phase II, multicenter, open-label pivotal trial in the European
Union (MCL-002-SPRINT), 254 patients with rrMCL were
randomized 2:1 to lenalidomide monotherapy or investigator’s
choice (IC) monotherapy (rituximab, gemcitabine, fludarabine,
chlorambucil, or cytarabine) [12]. At a median follow-up of 15.9
months, lenalidomide significantly improved progression-free
survival (PFS) compared with IC (median 8.7 vs. 5.2 months,
p5 .004). ORR was 40% (5% CR/CRu (unconfirmed CR)) for
lenalidomide and 11% (0% CR/CRu) for IC. Median duration of
response (DoR; 16.1 vs. 10.4 months) and OS (27.9 vs. 21.2
months) also encouraged the use of lenalidomide. The most
common grade 3 or 4 adverse events (AEs) were neutropenia
(44% vs. 34%) without increased risk of infection, thrombocyto-
penia (18% vs. 28%), leukopenia (8% vs. 11%), and anemia (8%
vs. 7%) in the lenalidomide and IC groups, respectively. Analysis
of subgroups and regression analyses associated better PFS
with lenalidomide than with IC therapy, irrespective of prior
treatment history [13]. In terms of combinations, lenalido-
mide plus chemotherapy or targeted agents has also been
investigated in patients with rrNHL [14–17]. The addition of
lenalidomide has resulted in favorable response rates and
improved outcomes. In a phase II study of patients with
relapsed/refractory indolent NHL, treatment with lenalido-
mide plus rituximab was associated with an ORR of 78%
among 18 evaluable patients, including a 33% CR rate. Lenali-
domide plus rituximab has also been investigated in patients
with rrMCL. In the phase II portion of a phase I/II study, ORR
was 57% among the 44 patients, and 36% achieved a CR [18].
A previous large report on patients who underwent lenalido-
mide treatment through named patient program (NPP)
showed an ORR of 45.5% in the MCL subset with a median
DoR of 8.8 months [19, 20].
Lenalidomide is available in Italy for patients with rrMCL
(without any other therapeutic options) since May 2011, based
on a local disposition of the Italian Drug Agency (AIFA) issued
according to a national law (Law 648/96: “medicinal products
that are provided free of charge on the National Health Serv-
ice”). An observational retrospective study was conducted in
24 Italian hematologic centers with the aim to improve infor-
mation on effectiveness and safety of lenalidomide when given
in everyday clinical practice.
SUBJECTS, MATERIALS, AND METHODS
Study Design
This was a multicenter, retrospective, observational study
aimed at collecting data on the effectiveness and the safety of
lenalidomide requested pursuant to Italian law 94/1998 in
rrMCL patients. All patients who underwent lenalidomide ther-
apy from 2011 to 2013 were deemed eligible for the study. A
total of 24 Italian centers that had made at least one request
for a supply of lenalidomide for nominal use were invited to
participate in the study. Institutional Review Boards/Independ-
ent Ethics Committees approved the study at each institute in
accordance with local rules and regulations (the Lenamant
Study, recorded in the AIFA Observational Studies Registry).
Participants gave their written informed consent in accordance
with the Declaration of Helsinki.
Objectives and Endpoints
The primary study objective was the effectiveness of lenalido-
mide in rrMCL patients, measured as ORR (defined as CR1 par-
tial response [PR] rate). The secondary objectives were survival
of patients (measured as PFS, OS, disease-free survival [DFS],
and DoR) and safety of lenalidomide (measured by recording
any AE and/or hospitalization that occurred during or immedi-
ately after treatment with the study drug).
Effectiveness Assessments and Statistical Methods
OS was calculated from start of treatment to the date of death
due to any cause and was censored at the last date the patient
was known to be alive. DFS was calculated for CR patients from
first documentation of response to the date of relapse or death
due to lymphoma or acute toxicity of treatment, whereas PFS
was calculated for all patients from the start of treatment to
relapse or death due to any cause. Duration of response was
2 Lenalidomide in Relapsed Mantle Cell Lymphoma
Oc AlphaMed Press 2018©Alpha ed Press 2018
Lenalidomide in Relapsed Mantle Cell Ly pho a1034
 by guest on February 12, 2019
http://theoncologist.alpham
edpress.org/
D
ow
nloaded from
 
calculated in CR or PR patients from the first documentation of
response to time of relapse or progression [21]. The determina-
tion of tumor response was based on the revised response cri-
teria for malignant lymphoma [21]. Definition of older patients
refers to the ones aged 65 years at lenalidomide start. Safety
and tolerability were evaluated according to the National Can-
cer Institute Common Terminology Criteria for Adverse Events
v4.0. Both patients treated with lenalidomide alone and with
lenalidomide in combination with another drug (dexametha-
sone or rituximab) were analyzed.
Demographics and patients’ characteristics as well as AEs
were summarized by descriptive statistics. Survival functions
were estimated by using the Kaplan-Meier method and were
compared using log-rank test. Statistical analyses were per-
formed with Stata 11 (StataCorp LLC, College Station, TX), and p
values were set at .05.
RESULTS
Patient Demographics
The total population included 70 patients: 52 were treated
with lenalidomide alone and 18 had combined therapy (13
received lenalidomide plus dexamethasone and 5 lenalidomide
and rituximab, respectively). Table 1 summarizes the character-
istics of all 70 evaluable patients. Median age at lenalidomide
was 67 (range 45–85) years; in particular, 57 patients (81.4%)
were aged 65 years at treatment start. The majority of the
population (71.4%) were male. The median number of prior
treatment regimens was 2.5 (range 1–10); 32 (45.7%) patients
were refractory to the last treatment, and 16 (22.8%) patients
were primary refractory.
Effectiveness
Overall, 688 cycles were completed for the 70 patients, with 11
(15.7%) patients receiving a 10mg/day dose, 16 (22.8%) patients
receiving a 15 mg/day dose, and 43 (61.5%) patients receiving a
25 mg/day dose. Of the 27 patients who received lenalidomide
at the dose of 10 or 15 mg, 4 had combination therapy. The ini-
tial dose depended on physician choice based on hematologic
parameters at baseline and known drug toxicities.
With a median of 8 cycles (range 1–55) and independently
by the drug dose, the ORR was 47.1%. A total of 22 (31.4%)
patients achieved a CR, 11 (15.7%) obtained a PR, 6 had SD,
and 31 showed PD. Among the 52 patients treated with mono-
therapy with lenalidomide, 14 (26.9%) achieved a CR and 5
(9.6%) obtained a PR, leading to an ORR of 36.5%. On the other
hand, in the combined therapy subset (18 patients), we
observed an ORR of 77.7% with eight (44.4%) CRs and six
(33.3%) PRs; more specifically, the two different combina-
tions (namely lenalidomide plus dexamethasone and lenali-
domide plus rituximab) did not show any statistically significant
Table 1. Patient demographics and characteristics at base-
line (n5 70)
Characteristics
Whole
population,
n5 70, n (%)
Patients in
continuous
complete
remission,
n5 14, n (%)
Median age, years (range) 67 (45–85) 63 (45–79)
<65 years 57 (81.4) 8 (57.1)
65 years 13 (18.6) 6 (42.9)
Male 50 (71.4) 8 (57.1)
Stage
I/II 14 (20.0) 4 (28.6)
III 5 (7.1) 1 (7.1)
IV 51 (72.9) 9 (62.3)
ECOG performance status
0/1 47 (67.1) 12 (85.7)
2 17 (24.3) 2 (14.3)
3 2 (2.9) —
4 1 (1.4) —
B symptoms 10 (14.3) 1 (7.1)
Refractory to most
recent therapy
32 (45.7) 4 (37.7)
Refractory to first-line therapy 16 (22.8) 9 (62.3)
Median number of previous
therapies (range)
2.5 (1–10) 2 (1–5)
Prior autologous stem
cell transplant
36 (51.4) 8 (57.1)
Lenalidomide single agents 52 (74.3) 8 (57.1)
Lenalidomide in combination 18 (25.7) 6 (42.9)
Abbreviations: —, no data; ECOG, Eastern Cooperative Oncology Group.
Figure 1. Progression-free survival of the whole study population
(A) and according to the monotherapy versus combined treatment
subsets (B).
Abbreviation: PFS, progression-free survival.
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difference in terms of ORR and CR rates. The ORR was higher in
patients who responded to last previous therapy (52.6%)
compared with those who were refractory (34.4%). Progres-
sive disease was found in 56.3% of refractory patients com-
pared with 39.5% of responding patients. There was no
significative difference in ORR between younger (38.5%) and
older (45.6%) patients.
Median DoR was 17.8 months and 19.4 months in patients
treated with monotherapy and combined therapy, respectively.
Outcome
At the latest available follow-up, 14 patients were in continuous
CR with a median follow-up of 26 months (range 13.8–62.7
months); specifically, 6 underwent combined therapy and 8
received lenalidomide as single agent. Table 1 summarizes the
clinical characteristics of these patients.
Median PFS was 13.8 months in all patients (Fig. 1A), and,
according to the monotherapy versus combined treatment sub-
sets, the median PFS was 26.3 months versus 12.1 months,
respectively (Fig. 1B, p< .001). Median DFS was 19.6 months
in all patients (Figure 2A), and, according to the monotherapy
versus combined treatment subsets, the median DFS was 19.6
months versus not reached, respectively (Fig. 2B, no significant
difference). Median OS was 32.5 months in all study population
(Fig. 3A), and, according to the single-agent versus combined
treatment subsets, the median OS was 31.4 versus 52.2
months, respectively (Fig. 3B, no significant difference). Glob-
ally, 26 patients died. No patient from this population was lost
to follow-up. A total of 34 patients (namely 8 who received
lenalidomide in combination with another drug and 26 who
received lenalidomide alone) underwent further treatment
after lenalidomide failure with a median time to the next treat-
ment of 3.4 months.
Safety
AEs were reported in 42 patients (60%), and SAEs were
reported in 9 patients (12.8%). Observed AEs in patients
included neutropenia (n5 25), thrombocytopenia (n5 6), ane-
mia (n5 6), and gastrointestinal toxicity (n5 4), which are con-
sistent with other published reports. Serious AEs included one
lung carcinoma, one myelodisplastic syndrome, two myocardial
infarctions judged not related to drug, and one infective epi-
sode and four gastrointestinal toxicities probably related to
lenalidomide. Besides progression of disease, other causes of
early discontinuation were the abovementioned 9 SAEs and 8
recurrent grade 4 neutropenia, for a total of 17 cases.
DISCUSSION
Lenalidomide, an immunomodulatory drug with direct antineo-
plastic effects, recently approved in the U.S. for rrMCL as single
Figure 2. Disease-free survival of the whole study population (A)
and according to the monotherapy versus combined treatment
subsets (B).
Abbreviation: DFS, disease-free survival.
Figure 3. Overall survival of the whole study population (A)
and according to the monotherapy versus combined treatment
subsets (B).
Abbreviation: OS, overall survival.
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agent, provided in several studies substantial ORR (28%–53%)
with durable activity (median DoR, 13.7–16.6 months) in heav-
ily pretreated patients, including those failing bortezomib [5]
and ibrutinib [22, 23]. Recent results fromMCL-002, a random-
ized phase II study of rrMCL patients, demonstrated a better
median PFS with lenalidomide than with investigator’s choice
[12, 13].
Lenalidomide plus rituximab has demonstrated activity in
several phase II studies across various NHL subpopulations in
the relapsed/refractory setting. For example, this combina-
tion regimen resulted in a 74% ORR (44% CR rate and 12.4
months median PFS) in patients with indolent lymphoma
and a 33% ORR (22% CR rate, 3.7 months median PFS, and
10.7 months median OS) in patients with aggressive lym-
phoma [14–16].
Based on established efficacy in multiple myeloma, lenali-
domide in combination with the anti-inflammatory agent dexa-
methasone was investigated in patients with heavily pretreated
rrMCL, obtaining an ORR of 52% [17, 18]. Besides the clinical
trials context, a retrospective report on a large NPP in Italy was
also published, but several types of lymphoma were included:
ORR was 42.2% in the whole population and 45.5% in the
rrMCL subset (n5 33) [20].
Our retrospective analysis on 70 patients reported that
ORR and CR rate were similar to those observed in clinical
trials investigating similar MCL populations treated with
lenalidomide as single agent or in combination with rituxi-
mab/dexamethasone. In fact, 26.9% of patients treated in
monotherapy with lenalidomide achieved a CR and 9.6%
obtained a PR with an ORR of 36.5%. In the combined ther-
apy subset, the ORR was 77.7% with a 44.4% CR rate. In addi-
tion, similar effectiveness was found among younger and
older patients.
The present study, which represents the largest report on
lenalidomide in rrMCL patients in the standard daily clinical
practice outside a trial setting, demonstrates that lenalidomide
is a feasible treatment option for patients with rrMCL, even in
real life. Separate analysis results for patients treated with lena-
lidomide alone or in combination (with dexamethasone or rit-
uximab) give a more precise idea on the activity and safety of
the drug to physicians who plan to use it, limiting bias in data
interpretation.
Lenalidomide was used in a wide spectrum of patients with
varied underlying diseases and a broad range of concomitant
medications; thus, the present data have the best picture of
the drug’s behavior in routine use.
CONCLUSION
Despite the known potential bias of all observational studies,
the present report on the real-life experience provides an
important contribution to medical knowledge. Treatment
with lenalidomide is effective and tolerable in everyday clini-
cal practice, with superimposable results to those obtained
in clinical trials, and it must be considered in the therapeutic
algorithm of rrMCL as a targeted approach [3, 10].
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For Further Reading:
Hun Ju Lee, Jorge E. Romaguera, Lei Feng et al. Phase II Study of Bortezomib in Combination with Cyclophosphamide
and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. The Oncologist 2017;22:549-553.
Implications for Practice:
The combination of bortezomib with cyclophosphamide and rituximab represents an additional effective novel
salvage regimen for mantle cell lymphoma. This combination adds to the growing list of treatment options available
for patients with mantle cell lymphoma.
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